Opdivo Approval Opens China I-O Doors But Pricing Key
China approves first immuno-oncology drug in the form of BMS’s Opdivo for lung cancer, opening up a new potentially huge market for the class, but much will depend on pricing and reimbursement policies.
You may also be interested in...
When Merck realized that demand in China is so large for its HPV vaccine Gardasil, the US company wanted to understand more about the market, but a coordinated pre-launch awareness campaign appears to have helped.
Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.
First comes the approval, then market access. A rapid regulatory clearance for BMS’s Opdivo in China not only pioneers a new and potentially huge market for immuno-oncology treatments, but may potentially set an example in how to expand market access for many new therapies waiting to get into the country, amid multiple recent regulatory and policy changes.